Literature DB >> 12464716

Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.

Dirk Dressler1, Reiner Benecke.   

Abstract

Recently, botulinum toxin type B (BT-B) has become available to treat muscle hyperactivity in cervical dystonia (CD). When we started the clinical use of BT-B, we noticed a side effect profile not seen with botulinum toxin type A (BT-A) before. Altogether 30 consecutive patients were included in this open controlled study. 24 patients were treated for CD with 11,310 +/- 2,616 mouse units (MU) of BT-B (NeuroBloc) and 6 for focal hyperhidrosis (HH) with 4,000-10,000 MU. In 5 of them, BT-A (Botox) was used additionally for comparison of effectiveness. In CD, side effects consisted of dryness of mouth (total 21, duration 4.4 +/- 2.0 weeks, 10 severe, 7 moderate, 4 mild), accommodation difficulties (7), conjunctival irritation (5), reduced sweating (4), swallowing difficulties (3), heartburn (3), constipation (3), bladder voiding difficulties (2), head instability (1), dryness of nasal mucosa (1) and thrush (1). In HH, side effects consisted of accommodation difficulties (4), dryness of mouth (2) and conjunctival irritation (1). Autonomic side effects occur far more often after BT-B than after BT-A. Their localization suggests systemic BT-B spread. BT-B should be applied carefully in patients with pre-existent autonomic dysfunction, additional anticholinergic treatment and in conditions where anticholinergics are contraindicated. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12464716     DOI: 10.1159/000067023

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  39 in total

Review 1.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

2.  [Pharmacology of botulinum toxin drugs].

Authors:  D Dressler
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

Review 3.  Botulinum neurotoxin - from laboratory to bedside.

Authors:  K A Foster; H Bigalke; K R Aoki
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 4.  Botulinum toxin therapy for cervical dystonia.

Authors:  J Jankovic
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

5.  Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.

Authors:  R Eleopra; V Tugnoli; R Quatrale; O Rossetto; C Montecucco; D Dressler
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 6.  [Pharmacological aspects of therapeutic botulinum toxin preparations].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 7.  Autonomic side effects of Botulinum toxin Type B intravesical injections: report of 4 cases and review of the literature.

Authors:  M Ghei; B H Maraj; S Nathan; J Malone-Lee; R Miller
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 8.  [Current outlook on botulinum toxin medications].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

Review 9.  Botulinum toxin drugs: future developments.

Authors:  D Dressler
Journal:  J Neural Transm (Vienna)       Date:  2008-03-28       Impact factor: 3.575

10.  Severity and impact of xerostomia in patients treated with botulinum toxin type b for cervical dystonia: Observations on the quality of life of patients with xerostomia.

Authors:  Patrick Hogan; P David Charles; Maureen Wooten Watts; Janice M Massey; Tamara Miller; John Mackowiack
Journal:  Curr Ther Res Clin Exp       Date:  2004-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.